Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mainz Biomed B.V. ( (MYNZ) ) just unveiled an announcement.
On January 27, 2025, Mainz Biomed NV announced that it regained compliance with all Nasdaq Capital Market listing requirements, following formal notification from Nasdaq on January 23, 2025. This development ensures the company’s continued listing and trading on Nasdaq, reinforcing its operational stability and market presence.
More about Mainz Biomed B.V.
Mainz Biomed NV is a molecular genetics diagnostic company focused on developing market-ready solutions for the early detection of life-threatening conditions. Its flagship product, ColoAlert®, is a non-invasive diagnostic test for colorectal cancer, marketed across Europe and the UAE, and is undergoing a pivotal FDA clinical study for US approval. The company also develops PancAlert, an early-stage pancreatic cancer screening test.
YTD Price Performance: 3.49%
Average Trading Volume: 131,702
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.89M
For a thorough assessment of MYNZ stock, go to TipRanks’ Stock Analysis page.
